PET/CT imaging with prostate-specific membrane antigen (PSMA)-targeted radioligands has emerged as an important diagnostic tool in prostate cancer (PC), outperforming conventional imaging modalities and previous generation radiopharmaceuticals in both primary staging and biochemical recurrence of the disease [1–6]. This evidence concerns the gene FOLH1 and Familial prostate cancer.